A. Ryan

发表

Pharmacokinetics, tissue distribution, and expression efficiency of plasmid [33P]DNA following intravenous administration of DNA/cationic lipid complexes in mice: use of a novel radionuclide approach.

P. Godowski, T. Gadek, G. Osaka, 1996, Journal of pharmaceutical sciences.

Immunohistochemical localization of PDE10A in the rat brain

Jerry Lanfear, J. Culp, F. Menniti, 2003, Brain Research.

Immunohistochemical Localization of Phosphodiesterase 10A in Multiple Mammalian Species

Daniel Morton, F. Menniti, D. Stephenson, 2006, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Kidney Pathology and Investigative Nephrotoxicology Strategies Across Species.

A. Ryan, Kendall S. Frazier, R. Peterson, 2019, Seminars in nephrology.

Comparative Nonclinical Assessments of the Proposed Biosimilar PF-05280014 and Trastuzumab (Herceptin®)

M. Leach, T. Smolarek, A. Ryan, 2014, BioDrugs.

Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation.

R. Cuthbertson, Y. Meng, A. Ryan, 1999, Toxicological sciences : an official journal of the Society of Toxicology.

Distribution of radioactivity and metabolite profiling in tumour and plasma following intravenous administration of a colchicine derivative (14C-ZD6126) to tumour-bearing mice

D. Roberts, A. Ryan, R. D'Souza, 2007, Xenobiotica; the fate of foreign compounds in biological systems.

20 – Biotechnology and Its Products

A. Ryan, T. Terrell, 2002 .

Frontiers in Nonclinical Drug Development

A. Ryan, 2015, Veterinary pathology.

Commentary: Role of the Pathologist in the Identification and Characterization of Therapeutic Molecules

A. Ryan, 1999, Toxicologic pathology.

Practical Aspects of Discovery Pathology

P. Germann, A. Ryan, J. Burkhardt, 2002, Toxicologic pathology.

Importance and impact of discovery pathology.

P. Germann, A. Ryan, J. Burkhardt, 2002, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

Development of a Method for Profiling Protein Interactions with LNA-Modified Antisense Oligonucleotides Using Protein Microarrays.

A. Ryan, L. Whiteley, Satoko Kakiuchi-Kiyota, 2016, Nucleic acid therapeutics.

Evaluation of the utility of popliteal lymph node examination in a cyclophosphamide model of immunotoxicity in the rat

J. Lapointe, A. Ryan, P. Haley, 2016, Journal of immunotoxicology.

Comparative Nonclinical Assessments of the Proposed Biosimilar PF-05280586 and Rituximab (MabThera®)

M. Leach, A. Ryan, Niraj Tripathi, 2014, Toxicologic pathology.

Expression of Proto-Oncogene cFMS Protein in Lung, Breast, and Ovarian Cancers

Paul W Brown, A. Ryan, P. Lappin, 2014, Applied immunohistochemistry & molecular morphology : AIMM.

Comparisons of the Intraocular Tissue Distribution, Pharmacokinetics, and Safety of 125I-Labeled Full-Length and Fab Antibodies in Rhesus Monkeys Following Intravitreal Administration

R. Cuthbertson, Y. Meng, A. Ryan, 1999, Toxicologic pathology.

Comparison of hepatic transcription profiles of locked ribonucleic acid antisense oligonucleotides: evidence of distinct pathways contributing to non-target mediated toxicity in mice.

A. Burdick, Ahmed Enayetallah, A. Ryan, 2014, Toxicological sciences : an official journal of the Society of Toxicology.

Morphogenesis of Postmortem Hepatocyte Vacuolation and Liver Weight Increases in Sprague-Dawley Rats

Ricardo Ochoa, A. Ryan, M. Elwell, 2003, Toxicologic pathology.

Preclinical Safety Evaluation of rhuMAbVEGF, an Antiangiogenic Humanized Monoclonal Antibody

R. L. Hall, G. Shopp, A. Ryan, 1999, Toxicologic pathology.

Bridging the species gap in translational research for neurodevelopmental disorders

A. Ryan, R. Berman, M. Bauman, 2019, Neurobiology of Learning and Memory.

2nd International Conference on Progressive Multifocal Leukoencephalopathy (PML) 2015: JCV virology, progressive multifocal leukoencephalopathy pathogenesis, diagnosis and risk stratification, and new approaches to prevention and treatment

Ilse S. Peterson, K. Tyler, E. Major, 2015, Journal of NeuroVirology.

Carol F. Kirchhoff, Hugh D. Conlon, Scott Anderson, 2017, Biotechnology and bioengineering.

Key considerations in the preclinical development of biosimilars.

Carol F. Kirchhoff, A. Ryan, Susan Hurst, 2015, Drug discovery today.

PHARMACOKINETICS AND RETINAL DISTRIBUTION OF RANIBIZUMAB, A HUMANIZED ANTIBODY FRAGMENT DIRECTED AGAINST VEGF-A, FOLLOWING INTRAVITREAL ADMINISTRATION IN RABBITS

L. Rangell, L. Damico, A. Ryan, 2007, Retina.

Microphysiological lung models to evaluate the safety of new pharmaceutical modalities: a biopharmaceutical perspective.

Myrtle Davis, Lorna Ewart, Andrew J Thorley, 2019, Lab on a chip.

The Society of Toxicologic Pathology and the “One Health” Initiative

S. Elmore, P. Snyder, P. Mann, 2010 .

Quantification of MPTP-induced dopaminergic neurodegeneration in the mouse substantia nigra by laser capture microdissection

Ricardo Ochoa, F. Menniti, Andres D. Ramirez, 2007, Journal of Neuroscience Methods.

Comparative Nonclinical Assessments of the Proposed Biosimilar PF-05280014 and Trastuzumab (Herceptin®)

M. Leach, T. Smolarek, A. Ryan, 2014, BioDrugs.

FutureTox II: Contemporary Concepts in Toxicology

S. Elmore, A. Ryan, T. Crabbs, 2014, Toxicologic pathology.